EN DE
Watch Tyra Biosciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tyra Biosciences Inc (TYRA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Tyra Biosciences Inc stock $16.11, price $19.74, that is 18.4% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US90240B1061

TB Tyra Biosciences Inc logo Thin data Nov 14, 2026

Tyra Biosciences Inc

TYRA · US

Expensive (fair value 18% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Insiders bought $20,002 (6M) 
Fair value $16.11 · Overvalued 
Quality 38/100 
Negative free cash flow 
Trails peers (1/6) 
Narrow moat 14/100 · thin data
Thin data 
Estimate
Watch Tyra Biosciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$39.61 $5.26 Fair Value $16.11 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $5.26 – $39.61 · fair‑value band $12.09 – $20.14 · the $19.74 price screens above the $16.11 fair value. As of Nov 14, 2026.

Follow Tyra Biosciences in your weekly email

Every Wednesday you see whether Tyra Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Show moreShow less

The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.

The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma.

Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Stock analysis

Tyra Biosciences Inc (TYRA) currently trades at $19.74, while our estimate is $16.11, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $12.09 (bear) to $20.14 (bull), the price of $19.74 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Tyra Biosciences Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$120M in FY2025.

Key figures

Market cap $1.3B Small · EPS (TTM) $−2.63 · Return on equity −34.9% · Return on assets (EBIT) −28.3% (5-year average) · Free cash flow −$95.3M · Net cash $71.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −18%, TYRA screens richer than that median.

Fair Value

Bear $12.09 Fair Value $16.11 Bull $20.14
Price $19.74 · Downside -18.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 25
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 40
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $20,002, on Sep 9, 2026.

  • BuyRehan VerjeeDirector972 shares at $20.58$20,002Sep 9, 2026
  • SaleGilla KaplanDirector14,295 shares at $36.97$528,486Mar 25, 2026
  • SaleDaniel BensenChief Discovery Officer5× since Nov 17, 2025: 169,661 shares, avg. $17.85$3.0MFeb 12, 202610b5-1 plan
  • SaleRobert J MoreDirector2× since Nov 21, 2025: 256,871 shares, avg. $20.43$5.2MDec 19, 202510b5-1 plan

Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TYRA screens overvalued: fair value 18% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Tyra Biosciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −18.4% · Above median
Profitability
Return on assets −42.4% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.03× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs TYRA
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs TYRA
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs TYRA
argenx SE ARGX $950.95 $908.40 −4% vs TYRA
CSL Limited CSL A$199.55 A$186.49 −7% vs TYRA
Moderna, Inc MRNA $215.27 $135.64 −37% vs TYRA
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs TYRA
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs TYRA
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs TYRA
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs TYRA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tyra Biosciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tyra Biosciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/TYRA

Frequently asked questions

Is Tyra Biosciences Inc (TYRA) overvalued or undervalued?
As of Nov 14, 2026, our estimate of fair value is $16.11 versus a price of $19.74, about 18% lower (overvalued).
What is the fair value of TYRA?
Our estimate for Tyra Biosciences Inc is $16.11 (as of Nov 14, 2026), built from audited fundamentals. The current price: $19.74.
What is the quality score of TYRA?
Tyra Biosciences Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tyra Biosciences Inc (TYRA)?
Our calculated price target is the estimate of $16.11 (as of Nov 14, 2026). Cautious scenario $12.09, optimistic scenario $20.14. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Tyra Biosciences Inc stock forecast for 2026?
Our estimate puts fair value at $16.11, about 18% lower versus a price of $19.74 (overvalued). Cautious scenario $12.09, optimistic scenario $20.14. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Tyra Biosciences Inc (TYRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tyra Biosciences Inc it is $16.11 per share (as of Nov 14, 2026), against a price of $19.74.
Is Tyra Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 14, 2026, TYRA trades above its calculated fair value: price $19.74, fair value $16.11, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TYRA?
No. The price is what the market pays today ($19.74); the fair value is what the company's own numbers justify ($16.11). For Tyra Biosciences Inc the two are $3.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tyra Biosciences Inc worth?
The market values Tyra Biosciences Inc at about $1.3B (market capitalisation, as of Nov 14, 2026). Per share that is $19.74; our models calculate a fair value of $16.11 per share.
What do the bullish and bearish scenarios say about TYRA?
Our models span a range for Tyra Biosciences Inc: cautious scenario $12.09, base $16.11, optimistic $20.14 per share (as of Nov 14, 2026, price $19.74). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tyra Biosciences Inc (TYRA)?
Balance-sheet figures for Tyra Biosciences Inc (as of Nov 14, 2026): return on equity −34.9%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is TYRA from its 52-week high?
Tyra Biosciences Inc trades at $19.74, about 50% below its 52-week high of $39.61 and 24% above the low of $15.90 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $16.11 is for.
Which stocks are comparable to Tyra Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tyra Biosciences Inc stock attractive at the current price?
The data as of Nov 14, 2026: price $19.74, calculated fair value $16.11 (−18%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Tyra Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tyra Biosciences Inc (TYRA)?
The closing price on Nov 16, 2026 was $19.74. Our estimate is $16.11, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tyra Biosciences Inc right now?
Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Tyra Biosciences Inc

How large is the market capitalisation of Tyra Biosciences Inc (TYRA)?
The market capitalisation of Tyra Biosciences Inc is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Tyra Biosciences Inc (TYRA)?
Earnings per share at Tyra Biosciences Inc are $−2.63. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Tyra Biosciences Inc (TYRA)?
The return on equity (ROE) of Tyra Biosciences Inc is −34.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tyra Biosciences Inc (TYRA)?
On an EBIT basis the return on assets of Tyra Biosciences Inc is −28.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Tyra Biosciences Inc (TYRA) generate?
The free cash flow of Tyra Biosciences Inc is −$95.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Tyra Biosciences Inc (TYRA) hold?
Tyra Biosciences Inc holds more cash than debt, $71.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Tyra Biosciences Inc in the live analysis

One click puts Tyra Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.